Supporting the Innovators who Optimize Therapeutic Decision-Making
Crosstree’s experience in the diagnostics and tools space is extensive, spanning routine chemistries to the most esoteric of testing, via either a product or service commercial approach. Molecular biology is reshaping the competitive landscape and Crosstree is at the forefront, facilitating synergistic transactions for a range of innovators in genomic and genetic testing and development.
No other partner is so uniquely equipped to assess and align the capabilities of diagnostics and tools companies with current market demands.
Diagnostics and Tools
Life Sciences
Tools
In Vitro
Diagnostics
Diagnostic
Services
In Vivo
Diagnostics
LIFE SCIENCES TOOLS
- Consumables
- Instrumentation
- Lab/Biobank Equipment
- Laboratory Software
IN VITRO DIAGNOSTICS
- Chemistry
- Hematology & Coagulation
- Histology & Cytology
- Immunodiagnostics
- Microbiology
- Molecular
DIAGNOSTIC SERVICES
- Diagnostic Imaging
- General Chemistry
- Specialized Testing
- Toxicology
IN VIVO DIAGNOSTICS
- Biometric Monitoring
- Imaging Diagnostics
Bluebooks
Explore our industry-specific Bluebooks for comprehensive monthly coverage of M&A, recapitalization, and growth financing transactions, along with year-on-year comparisons. Subscribe to your relevant BlueBook for valuable insights today.
Latest Diagnostics and Tools Transactions
Grant Avenue Capital Recapitalizes CREO
QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally
Versiti Acquired Quantigen to Further Expand Clinical Trial Expertise and Service Offering
Access Medical Labs Allies with Grupo Diagnostico Aries to Expand Diagnostic Lab Capabilities into North America
Grenova Completes Growth Recapitalization with Peloton Equity to Accelerate Strategic Objectives
PreventionGenetics acquired by Exact Sciences to Enable Earlier Cancer Detection and Hereditary Cancer Testing
ZebraSci Acquired by BD to Enhance Combination Product Testing Capabilities
Pyxant Labs Receives Majority Investment from ArchiMed
Pyxant Labs Bolsters Capabilities in Acquisition of Covance by Labcorp’s SLC Bioanalytical Site
Haematologic Technologies, Inc. was acquired by Edgewater Capital Partners
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
HistoGeneX combines with Caprion Biosciences via strategic investment from Arsenal Capital Partners
MolecularMD has been acquired by ICON Plc.
Santus Laboratories (owned by HealthEdge Partners) sold Cough/Cold asset to Reliable1 – October 2018
Transposagen Biopharmaceuticals, Inc. has been acquired by Lonza
PhenoPath has been acquired by Quest Diagnostics September 2018
Santus Laboratories (owned by HealthEdge Partners) was purchased by DermaRite (owned by Tailwind Capital Group) August 2018
OmniSeq Received a Strategic Investment from HITACHI April 12, 2018
MedLabs Diagnostics Recapitalized by Caymus Equity and PNC Mezzanine Capital April 3, 2018
